Obesity continues to grab attention at the JP Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

Immuron Ltd (ASX:IMC) has moved through a series of development milestones for its drug Travelan: which aims at preventing ...

The US company has said it is launching the Phase III trials in the first half of this year after Phase I talks with the US ...

Eight blockbuster drugs are expected to generate over $3bn in peak sales each according to Novartis CEO Vas Narasimhan.

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus ... helping to guide future development,” it added. The study also included two other ...

These data will be used to determine the next phase of development. Discovery: C4T will continue to utilize its TORPEDO ® platform to develop orally bioavailable degraders for oncology and ...

NDAQ:KYMR) Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral ...

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that an independent DSMB, which conducted a planned review of the 30-day safety data from a ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Commissioner Robert Califf, M.D., and other senior FDA officials recently published a “Special Communication” in JAMA describing FDA’s concerns with the use of AI in medical product development, ...

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that it has submitted the Clinical Study Report to the U.S. Food ...